Roughly 30% of patients with metastatic prostate cancer and 32% of those with advanced urothelial cancer underwent next-generation sequencing. Most patients with advanced prostate cancer or urothelial ...

Treatment preferences between survival and quality of life and their association with clinical outcomes in older adults with advanced cancer. Rates of first NGS relative to the time of death (in pts ...

FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress ...

Mr. Han may continue to purchase the Company’s ADSs through open-market transactions, privately negotiated transactions or block trades, or other legally permissible means, depending on market ...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual ...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress ...

Attitudes and knowledge towards breast cancer among non-healthcare workers at an educational institution. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care Symposium. This abstract does ...

“Emerging technologies leveraging ctDNA and NGS are increasing our ability to identify cancers in high-risk patients, which was previously beyond reach,” said Dr. Nathan Montgomery, Vice President of ...

GUANGZHOU, China, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (BNR) (NASDAQ: BNR, the “Company” or “Burning Rock”), an innovative company in the field of precision oncology, and ...

New xGen™ hybridization and wash offering is poised to revolutionize targeted next generation sequencing workflows Integrated DNA Technologies' new xGen™ Hybridization and Wash v3 Kit is poised to ...